David Bredt - 06 Jun 2024 Form 3 Insider Report for Rapport Therapeutics, Inc. (RAPP)

Role
Chief Scientific Officer
Signature
/s/ Cheryl Gault, Attorney-in-Fact
Issuer symbol
RAPP
Transactions as of
06 Jun 2024
Net transactions value
$0
Form type
3
Filing time
06 Jun 2024, 19:03:13 UTC
Next filing
04 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding RAPP Common Stock 477,642 06 Jun 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RAPP Stock Option (Right to Buy) 06 Jun 2024 Common Stock 94,080 $1.80 Direct F1
holding RAPP Stock Option (Right to Buy) 06 Jun 2024 Common Stock 70,378 $9.60 Direct F2
holding RAPP Stock Option (Right to Buy) 06 Jun 2024 Common Stock 31,524 $11.57 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this option shall vest and become exercisable on August 7, 2024, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F2 25% of the shares underlying this option shall vest and become exercisable on March 25, 2025, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F3 25% of the shares underlying this option shall vest and become exercisable on May 1, 2025, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney